LEP and immune system disorder: Indeed, in several prospective case studies, leptin replacement therapy (with subcutaneous human recombinant methionyl leptin) for 4 to 8 months has been shown to improve immune dysfunction in patients with generalized forms of lipodystrophy, normalizing absolute number and relative percentages of T lymphocyte subsets and increasing TNF-α secretion in PBMC [131].